Amgen Inc. (NASDAQ:AMGN) Shares Bought by Global Wealth Management Investment Advisory Inc.

Global Wealth Management Investment Advisory Inc. grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 26.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 6,867 shares of the medical research company’s stock after buying an additional 1,438 shares during the quarter. Global Wealth Management Investment Advisory Inc.’s holdings in Amgen were worth $1,790,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Wingate Wealth Advisors Inc. purchased a new position in Amgen in the fourth quarter valued at $52,000. MBA Advisors LLC raised its position in Amgen by 2.0% in the 4th quarter. MBA Advisors LLC now owns 2,909 shares of the medical research company’s stock valued at $758,000 after purchasing an additional 57 shares in the last quarter. Ferguson Wellman Capital Management Inc. boosted its stake in shares of Amgen by 1.2% in the 4th quarter. Ferguson Wellman Capital Management Inc. now owns 20,159 shares of the medical research company’s stock valued at $5,254,000 after buying an additional 242 shares during the period. OMC Financial Services LTD acquired a new position in shares of Amgen during the fourth quarter worth about $730,000. Finally, Compass Financial Services Inc purchased a new stake in shares of Amgen during the fourth quarter worth approximately $69,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.69% of the company’s stock.

Amgen Trading Down 1.4 %

Shares of AMGN stock opened at $293.54 on Monday. The firm’s 50-day simple moving average is $272.26 and its 200-day simple moving average is $303.00. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.96. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The firm has a market cap of $157.79 billion, a P/E ratio of 38.88, a PEG ratio of 3.01 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, equities analysts forecast that Amgen Inc. will post 20.59 EPS for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.24%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s payout ratio is currently 119.21%.

Analyst Ratings Changes

AMGN has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Leerink Partners lowered their target price on shares of Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Truist Financial cut their price target on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research note on Wednesday, January 8th. UBS Group lowered their price objective on Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research report on Thursday, October 31st. Finally, Wells Fargo & Company cut their target price on Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a research report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $314.09.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.